An interventional study of eShunt Implant in Hydrocephalus, Normal Pressure and Hydrocephalus, sponsored by CereVasc Inc. Active, not recruiting at 11 sites in United States. Open to participants aged 65 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-06-19.
Sponsored by CereVasc Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Hydrocephalus, Normal Pressure with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Hydrocephalus, Normal Pressure · United States.
Among the 24 studies in Hydrocephalus, Normal Pressure with a site in United States, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 10 with no phase, and was the 21st registered.
78 studies on the registry are indexed under Hydrocephalus, Normal Pressure; 20 are open to participants now.
Browse Hydrocephalus, Normal Pressure studies →4 of the 24 studies in Hydrocephalus, Normal Pressure with a site in United States are open now. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 60–99
University of South Florida · Sites in United States
Ages 40+
University of South Florida · Sites in United States
Ages 40+
Johns Hopkins Bloomberg School of Public Health · Sites in United States
Ages 65+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Hydrocephalus, Normal Pressure studies recruiting now, 12 (75%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 65 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 49 across 40 interventional studies indexed under Hydrocephalus, Normal Pressure.
Median enrollment 30 across the 15 interventional studies, 20 across the 9 observational. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 24 have an industry lead sponsor. The 10 most frequent:
CereVasc Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.
CereVasc Inc has 3 studies filed under Hydrocephalus, Normal Pressure — fewer than ten, so there is no comparison to draw.
4 of the studies in Hydrocephalus, Normal Pressure with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04011566University of South FloridaAssessment of ShuntCheck Performance Characteristics in Asymptomatic Patients With Normal Pressure Hydrocephalus | 2026-11 |
| NCT06498960CereVasc IncEvaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus | 2027-01 |
| NCT04309487University of South FloridaDiagnostic Accuracy of ShuntCheck Compared to Radionuclide Shunt: Patency in Patients With Normal Pressure Hydrocephalus | 2027-01 |
| NCT06426004Johns Hopkins Bloomberg School of Public HealthAddressing Health Disparities in Normal Pressure Hydrocephalus (NPH) in Maryland | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 24 studies in Hydrocephalus, Normal Pressure with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
This is a prospective, non-randomized, open-label, multi-center, pilot study in subjects with normal pressure hydrocephalus for whom a traditional cerebrospinal fluid (CSF) shunt implant is indicated.
Up to 50 subjects will receive the eShunt Implant at up to 12 investigational sites. It is anticipated that up to 250 patients may need to be enrolled (consented) in order to result in 50 subjects who qualify according to the inclusion/exclusion criteria. Subjects will return for five follow-up visits in the first year and then continue to attend visits every six months until the study is closed or up to five years post-implantation.
The study objectives are to demonstrate safety of the eShunt Procedure, as well as demonstrate safety and efficacy of the eShunt Implant in a small sample of patients. Subjects will be followed long-term; primary analysis results will be used to support additional studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical presentation consistent with NPH including 2 or more of the clinical triad (i.e., history of gait disturbance, progressive mental deterioration, and urinary urgency or incontinence), together with:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Treatment Arm receives the eShunt Implant.
Device: eShunt Implant
The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
Device and/or procedure-related serious adverse events (SAEs)
Rate of occurrence of device and/or procedure-related serious adverse events (SAEs)
Time frame: 90 days following eShunt Implant deployment
Number of participants with abnormal MRI findings
Number of participants with abnormal MRI findings and descriptive summaries of findings
Time frame: 90 days following eShunt Implant deployment
Number of participants with abnormal CT findings
Number of participants with abnormal CT findings and descriptive summaries of findings
Time frame: 90 days following eShunt Implant deployment
Number of participants with clinically significant abnormal complete blood count (CBC) results
Number of participants with clinically significant abnormal results and descriptive summaries of CBC results
Time frame: 90, 180, and 365 days following eShunt Implant deployment
Number of participants with clinically significant abnormal blood chemistry results
Number of participants with clinically significant abnormal findings and descriptive summaries of blood chemistry results
Time frame: 90, 180, and 365 days following eShunt Implant deployment
Number of participants with clinically significant abnormal neurological exam findings
Number of participants with clinically significant abnormal findings and descriptive summaries of neurological exam findings
Time frame: 90, 180, and 365 days following eShunt Implant deployment and at study completion
Number of participants with adverse events
Tabulation of all adverse events
Time frame: 90, 180 and 365 days following eShunt Implant deployment and at study completion
Change in gait compared to baseline
Change in gait compared to baseline as measured by the duration in seconds of the Timed Up and Go Test (shorter durations indicate improvement (increased mobility))
Time frame: 90, 180 and 365 days following eShunt Implant deployment
Change in cognitive ability compared to baseline
Change in cognitive ability compared to baseline as measured by Montreal Cognitive Assessment (MoCA) scores (scores range from 0-30; higher scores indicate improvement (less cognitive disability))
Time frame: 90, 180 and 365 days following eShunt Implant deployment
Change in urinary symptoms compared to baseline
Change in urinary symptoms compared to baseline as measured by the Neurogenic Bladder Symptom Score (NBSS) (scores range from 0-28; lower scores indicate improvement (fewer symptoms))
Time frame: 90, 180 and 365 days following eShunt Implant deployment
Change in Modified Rankin Scale compared to baseline
Change in degree of disability compared to baseline as measured by Modified Rankin Scale (mRS) scores (scores range from 0-6; lower scores indicate improvement (less disability))
Time frame: 90, 180 and 365 days following eShunt Implant deployment
Plan to share: No
Ran from Apr 2022 to primary completion in Jun 2025, 37 months.
Of 21 interventional studies with no phase under Hydrocephalus, Normal Pressure, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hydrocephalus, Normal Pressure →
CereVasc Inc